Bank of America Has Lowered Expectations for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA) had its price target trimmed by Bank of America from $36.00 to $29.00 in a research note published on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts have also commented on the company. Wedbush reiterated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Thursday, November 21st. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a report on Tuesday, November 19th. Finally, HC Wainwright raised their price target on shares of Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, November 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $29.38.

Kura Oncology Stock Up 1.5 %

KURA stock opened at $10.96 on Friday. Kura Oncology has a 52 week low of $9.06 and a 52 week high of $24.17. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a 50-day simple moving average of $17.88 and a 200-day simple moving average of $19.67. The stock has a market capitalization of $852.25 million, a P/E ratio of -4.64 and a beta of 0.86.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently bought and sold shares of KURA. Suvretta Capital Management LLC grew its stake in shares of Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after buying an additional 583,155 shares during the period. Assenagon Asset Management S.A. grew its position in Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after acquiring an additional 577,732 shares during the period. Sofinnova Investments Inc. increased its stake in Kura Oncology by 64.4% during the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after acquiring an additional 323,303 shares during the last quarter. Armistice Capital LLC increased its stake in Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after acquiring an additional 302,000 shares during the last quarter. Finally, Alethea Capital Management LLC raised its position in Kura Oncology by 108.2% in the third quarter. Alethea Capital Management LLC now owns 553,542 shares of the company’s stock valued at $10,816,000 after purchasing an additional 287,636 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.